Premium
Initial human experience with the Amplatzer perimembranous ventricular septal occluder device
Author(s) -
Bass John L.,
Kalra G.S.,
Arora Ramesh,
Masura Jozef,
Gavora Pavlo,
Thanopoulos Basil D.,
Torres William,
Sievert Horst,
Carminati Mario,
Fischer Gunther,
Ewert Peter
Publication year - 2003
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.10406
Subject(s) - medicine , shunt (medical) , cardiology , embolization , tricuspid insufficiency , aortic valve , heart septal defect , aortic valve insufficiency , surgery , tricuspid valve
Transcatheter closure of perimembranous ventricular septal defects with coils or devices designed to close other lesions may be complicated by embolization or aortic insufficiency. A new asymmetric Amplatzer perimembranous ventricular septal occluder and delivery system was specifically designed for perimembranous defects. This report describes the first use of this device in 27 patients. Implantation was successful in 25 (93%), with 1 removed for device‐related aortic insufficiency and inability to position the delivery sheath in another. Device orientation was excellent when the device was initially advanced through a standard delivery sheath positioned in the left ventricular apex. Twenty‐three had complete occlusion within 1 week (92%), with a tiny (< 2 mm) residual shunt in the other two. In the 25 subjects with the device left in place, device‐related aortic or tricuspid insufficiency, arrhythmias, and embolization were not observed. These excellent acute results need to be confirmed by long‐term follow‐up. Cathet Cardiovasc Intervent 2003;58:238–245. © 2003 Wiley‐Liss, Inc.